Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.

Kai-Cai LiuYing-Hong HaoWei-Fu LvWei-Dong JiaChu-Shu JiChun-Ze ZhouDe-Lei ChengShao-Bao XuZong-Gen GaoMing-Xue SuChang-Sheng Shi

Published in: Drug design, development and therapy (2020)

Compared with TACE treatment alone, TACE combined with sorafenib in BCLC-C stage HCC significantly improved disease control rate, TTP, and OS, and no significant increase in adverse reactions was observed.

Keyphrases

radiofrequency ablation
emergency department
adverse drug